Asensus Surgical has agreed to be acquired by KARL STORZ, an endoscopy expert that will continue developing its robotic systems.

TransEnterix changed its name to Asensus Surgical and introduced a new category of surgery to its offerings. Research Triangle Park, N.C.-based Asensus Surgical said the name change represents its broader vision of shaping the future of surgery by integrating computer vision and machine learning with surgical robotics. Sensus is Latin for “cognition,” highlighting the connection…

TransEnterix received CE Mark approval for its Intelligent Surgical Unit for the Senhance system. The Intelligent Surgical Unit (ISU) enables machine vision capabilities on the Senhance surgical system, providing digital laparoscopic programs in Europe to be augmented by intelligence capabilities in surgical settings. The FDA cleared the ISU in March 2020. Research Triangle Park, N.C.-basd…

In July 2020, autonomous vehicles, industrial automation, and surgical robots continued to receive funding at steady levels in comparison with the same period last year.

TransEnterix’s newly approved Intelligent Surgical Unit enables augmented intelligence for the Senhance laparoscopic surgical system.

TransEnterix’s new technology is designed to enable augmented intelligence with its Senhance system for robot-assisted surgery.

TransEnterix is publicly offering stock after regulatory approvals of its Senhance robotic surgical system and disappointing financial results.

Japanese regulators approved TransEnterix‘s Senhance robot-assisted surgery device for several procedures. Japan’s Ministry of Health, Labor & Welfare granted “shonin” approval to Senhance for laparoscopy for general surgery, gynecology, urology and “certain thoracic procedures,” the Research Triangle Park, N.C.-based company said. “Regulatory approval in Japan is a pivotal milestone for our company, as Japan is…

Robot-assisted surgery is growing, as new technology enables applications for additional operations. AdventHealth for Women in Florida is an early user of TransEnterix’s Senhance for gynecological procedures.

TransEnterix has won expanded indications from the Food and Drug Administration for its Senhance robot-assisted surgical system. The system is now cleared for hernia and gallbladder procedures. There are approximately 760,000 inguinal hernia and 1.2 million laparoscopic cholecystectomy procedures performed annually in the U.S. With this clearance, the system’s total addressable annual procedures in the…

TransEnterix (NYSE:TRXC) said today that it agreed to deal its SurgiBot assets to Chinese medtech investment firm Great Belief International for $29 million. The agreement calls for Research Triangle Park, N.C.-based TransEnterix to retain the distribution rights to SurgiBot, which it shelved last year, outside of the U.S. The FDA in April 2016  denied 510(k) clearance for…

The surgical robotics market in the US has finally become competitive. In October, the FDA granted clearance to only the second robotic surgical system to date – the TransEnterix Senhance laparoscopic platform. The clearance was a huge milestone for the Morrisville, N.C.-based company and was quickly followed by yet another – almost exactly a month…

TransEnterix (NYSE:TRXC) shares jumped today after the medical device company said it sold its first Senhance robot-assisted surgery platform in the U.S., exactly a month after winning FDA clearance. The sale, to Florida Hospital in Orlando, follows another sale in Taiwan made during the third quarter, president & CEO Todd Pope said during a conference call…

Share prices for TransEnterix (NYSE:TRXC) have more than doubled since the robot-assisted surgery company won an important clearance from the FDA last week and CEO Todd Pope is optimistic about his companies chances against the undisputed market leader, Intuitive Surgical (NSDQ:ISRG). Morrisville, N.C.-based TransEnterix, which acquired Senhance for $100 million in September 2015, finalized its clearance bid last…

TransEnterix (NYSE:TRXC) said last week that it won 510(k) clearance from the FDA for its Senhance robot-assisted surgery platform. TransEnterix, which acquired Senhance for $100 million in September 2015, finalized its clearance bid last month after applying in April.  “The clearance of the Senhance system in the U.S. is a milestone in the progress of robotics and is…

TransEnterix (NYSE:TRXC) last week won the dismissal of a shareholders lawsuit brought over the collapse of its SurgiBot program, with a federal judge ruling that the company and its management and investors didn’t mislead shareholders about the robot-assisted surgery platform’s prospects with the FDA. The case dates back to the spring of 2016, when Research Triangle Park,…

Robotics medical company TransEnterix filed its response to the Food and Drug Administration’s additional information request on its Senhance Surgical Robotic System 510(k) submission. The Senhance robotic-assisted surgery system is designed to improve minimally invasive surgery, namely in laparoscopy operations, through haptic feedback and eye sensing camera control. “We are very pleased to have submitted…